The anti‐PD‐1 monoclonal antibody cemiplimab was investigated as frontline monotherapy for advanced NSCLC with PD‐L1 TPS ≥ 50% in the global Phase III EMPOWER‐Lung 1 trial (NCT03088540) [20]. Here, CD274 is linked to non-small cell lung carcinoma.